Author Index

Agyik A, 563
Alexander GC, 361, 403
Allison-Levick J, 20

Babb J, 188
Baine D, 563
Bass-Ringdahl S, 383
Bauch CD, 181
Beattie RC, 471
Beatty CW, 225
Bendix Gottlieb A, 157
Berlin CI, 283, 302, 314
Beyer CM, 403
Bobal AM, 239
Bobbin RP, 286
Boothroyd A, 72
Bordelon J, 302
Brashears SM, 314
Bratt GW, 444
Breneman A, 188
Brinin C, 563
Burchfield SB, 372

Cacace AT, 280
Campbell KCM, 124, 134, 144, 157
Champlin CA, 557
Chermak GD, 280
Collet L, 339
Cox RM, 361, 403
Cranford JL, 251
Culbertson DS, 9
Cunningham DR, 39

Dockray J, 20
Dorr MB, 157
Driscoll CLW, 188, 225
Drury SS, 296
Duclaux R, 339
Durrant JD, 339

Elangovan S, 251
Elkayam J, 485
Ellingson RM, 239
Ellison JC, 59
English K, 485
Ewert C, 347

Fabry DA, 225
Fabry L, 188
Fausti SA, 239, 444
Feeney MP, 574
Flick CL, 239
Franz K, 202

Gates GA, 574
Gordon JS, 444
Gray GA, 361
Greenwald RR, 434

Hall SE, 518
Hanks WD, 383
Harkrider AW, 372
Harris FP, 59
Harrys R, 20
Hedgecock LD, 173
Hegarty J, 20
Helt WJ, 444
Henry JA, 239
Henshall KR, 582
Herbstein N, 29
Hickson L, 414
Higdon RJ, 574
Hoglin SL, 56
Holloway C, 363
Holte L, 383
Hood LJ, 285, 302, 314
Hughes L, 124, 134, 144, 157
Hurley RM, 510
Jacobson GP, 231, 393
Jenstad LM, 347
Jerger J, 434
Keats BJB, 296
Kei J, 20, 563
Keith RW, 278
Kelly E, 157
Kelly JK, 525
Kirkegard C, 20
Klemens JJ, 134
Klumpp ML, 260
Kornhass S, 536
Kosky C, 72
Kuk PK, 84, 119, 169

Lapillonne A, 339
Larsen DL, 124
Lee L, 84
Lehman ME, 100
Leighton A, 157
Lutolf JJ, 109
Lynn SG, 181
Marcoux A, 119, 169
Margolis RH, 383
Matteson EI, 225
Maurer M, 20
McCaslin DL, 231, 393
McDonald TJ, 225
McFarland DJ, 280
McKay CM, 582
Meech RP, 124, 134, 144
Mellon MW, 181
Mitchell CR, 239
Moncrieff DW, 1
Morlet TG, 314, 339
Muller T, 59
Murnane OD, 500, 525
Nabelek AK, 372
Nelson MD, 536
Noffsinger D, 444
Olsen WO, 173
O'Malley H, 109
Onyenekwu NN, 286
Parker MS, 286
Peterson A, 188
Phillips DP, 518
Phillips DS, 444
Pilirrillo J, 84
Pillion AL, 1
Plyer PN, 260
Potts L, 84
Pravica D, 251
Preminger JE, 39, 545
Proffitt TM, 500
Putet G, 339
Ricci A, 325
Robinettie MS, 213
Rogers DS, 372
Rose BE, 173
Rose K, 302
Rybak LP, 124, 144
Scherer J, 100
Scudder SG, 9
Seikel T, 280
Shallop J, 188
Shetty SR, 557
Silman S, 109
Small SA, 556
Sockalingam R, 563
Somani S, 134
Souza PE, 427
Spirakies SE, 510
Stapells DR, 556
Stewart J, 9
Stewart M, 100
Stoeckel R, 188
Strome SE, 225
Stuart A, 251
Sugiura KM, 444
Targovnik N, 157
Thyer N, 414
Townsend EA, 1

593
Key Word Index

1/6th-octave steps, 444
Acceptable noise levels, 372
Acclimatization, 84
Acoustic admittance, 20, 109
Acoustic analysis, 414
Acoustic compliant susceptance, 109
Acoustic compliant reactance, 109
Acoustic conductance, 109
Acoustic hemifield, 518
Acoustic impedance, 109
Acoustic reflex, 109
Acoustic-reflex growth function, 109
Acoustic resistance, 109
Active process, 325
Adaptation, 325
Adult hearing loss, 9
Adults, 347, 563
Aerobics, 29
Aging, 427, 574
Amikacin, 134
Aminoglycosides, 134
Antioxidants, 134, 144
Antiphase, 1
Articulation index, 574
ATP, 286
Attenuation, 260
Asymmetries, 339
Audiologic monitoring, 157
Audiologic rehabilitation, 545
Audiological assessments, 563
Audiology, 269
Auditory brainstem response, 144, 188, 239, 302, 556
Auditory dys-synchrony, 302
Auditory event-related potentials, 251
Auditory evoked potentials, 251
Auditory neuropathy, 188, 213, 302, 574
Auditory perception, 72
Auditory processing, 536
Autoimmune inner ear disease, 225
B-71, 556
Background noise level, 372
Bilingual, 557
Bone-conduction hearing thresholds, 556
Brief-tone stimuli, 556
Bth mouse, 296
Catalase, 144
Cisplatin, 124, 144
Cisplatin chemotherapy, 202
Click-evoked otoacoustic emission, 525
Clicks, 239
Clinical trials, 157
Cochlea, 202
Cochlear aqueduct, 510
Cochlear development, 339
Cochlear implants, 188, 582
Communication strategies, 545
Compression, 59
Compression amplification, 414
Compression attack time, 59
Compression ratio, 59
Compression release time, 59
Compression threshold, 59
Counseling, 485
Cross-check principle, 269
Dalbavancin, 157
Diclofenac, 536
Dichotic chords, 536
Dichotic CVs, 536
Dichotic digits, 536
Digital power hearing aid, 84
Directed recall, 536
Distortion product otoacoustic emissions (DPOAE), 9, 202, 471
Dizziness, 231
Dizziness Handicap Inventory, 231
dn mouse, 296
Ear advantage, 434
Early detection, 444
Efferent system, 302
Electrical auditory brainstem response, 188
Electromyography, 500
Electronystagmography, 231
Enzymes, 144
Evaluation studies, 39
Evoked potentials, 393
Experts, 347
False alarm rate, 269
Farming population, 100
FDA, 157
Fine-tuning, 347
Forward masking, 302
Frequency response, 582
Gating compliance, 325
Gender, 213
Gender difference, 372
General Severity Index, 181
Gentamicin, 202
Glutathione, 124
Glutathione ester, 124
Glutathione peroxidase, 144
Glutathione reductase, 144
Glycopeptide, 157
Grason-Stadler GSI-60, 471
Hair bundle, 325
Hearing, 144, 202, 269
Hearing aids, 39, 347, 403
Hearing conservation, 29
Hearing disorder, 302
Hearing handicap, 100, 545
Hearing-in-Noise Test, 518
Hearing loss, 72, 124, 134, 225, 347, 361, 403, 427, 444, 453, 485, 510
Hearing protection device, 260
Hearing screening, 9
Hearing test, 72
High-frequency audiometry, 157
High-frequency hearing loss, 100, 525
High-frequency tympanometry, 20
Hit rate, 269
Homophasic, 1
Human, 302, 314
Hydrocephalus, 510
Individualized sensitive frequency range, 444
Infant hearing, 383
Input-output functions, 471
Interhemispheric processing, 434
Knowles Electronics Manikin for Acoustic Research, 59
Laterality, 434
Linear amplification, 414
Low compression threshold, 84
L-type calcium channel, 202
Magnesium deficiency, 202
Malondiadehyde, 144
Masking, 427
Masking-level difference, 1
Met channels, 325
Metabotropic receptor, 286
Methotrexate, 225
Middle ear, 20
Middle-ear muscle reflex, 302, 314
Mismatch negativity, 251
Most comfortable listening level, 372
Motor evoked potentials, 500
Multitalker babble, 453
Musicians, 314, 536
N100, 393, 434
Neonate, 20
Neonatal hearing screening, 20
Neural dys-synchrony, 188
Neural synchrony, 188
Neurotransmitter, 286
Nitric oxide, 202
NMDA, 202
Noise, 202, 518
Noise-induced hearing loss, 100
Nonsynormic hereditary hearing loss, 296
Occlusion effect, 556
Older adult, 403
Olivocochlear reflex, 302
Otoacoustic emissions, 188, 213, 302, 314, 339, 383, 510
Otoscope, 9
Ototoxicity, 124, 134, 144, 239, 444
Ototoxicity monitoring, 157
Outcomes assessment 403
Outer hair cells, 124, 202, 339
P300, 434
Permanent threshold shift, 260
PET Scan, 225
Phase I, 157
Phonetic contrast perception, 72
Presbycusis, 574
Prescriptive formula, 59
Pre-term neonates, 339
Principal components analysis, 347
Probe-tone frequency, 109
Psychological distress, 181
Pure-tone average, 100
Pure-tone screening, 9
Questionnaires, 485
Recreational noise-induced hearing loss, 29
Rehabilitation of hearing impaired, 545
Saccule, 500
Salicylate, 202
Self-assessment of hearing impairment, 9
Sensorineural, 347
Sensorineural hearing loss, 225
Sequential presentation of primary-tone pairs, 471
Signal-to-babble ratio, 453
Signal-to-noise ratio, 372
Simultaneous presentation of primary-tone pairs, 471
Spatial masking, 518
Speech, 251
Speech envelope, 59
Speech intelligibility, 361
Speech perception, 188, 414, 453, 557, 582
Speech perception test, 72
Speech processing strategy, 188
Speech reception threshold, 518, 557
Sternocleidomastoid muscle, 500
Subjective, 347
Subjective outcomes, 361
Sudden hearing loss, 213
Superoxide dismutase, 144
Suppression of otoacoustic emission, 314
Symptom Checklist-90-R, 181
Temporary threshold shift, 260
Test battery, 269
Test correlation, 269
Test protocol, 269
Test-retest reliability, 471
Threshold, 427
Tinnitus, 181, 393
Tinnitus Handicap Inventory, 181
Tinnitus retraining therapy, 181
Tmc1 gene, 296
Tone bursts, 239
Transient-evoked otoacoustic emissions, 292, 213, 314, 525, 563
Tympanometry, 383
Universal newborn hearing screening, 383
Ventriculoperitoneal shunt, 510
Vestibular compensation, 231
Vestibular nerve, 500
Vestibular function tests, 500
Word recognition, 574
Young adults with normal hearing, 1